Page last updated: 2024-10-28

lidocaine and Depression

lidocaine has been researched along with Depression in 20 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
"This study evaluated the analgesic efficacy and emotional response to intravenous lidocaine infusion compared with placebo in patients with postherpetic neuralgia (PHN)."9.27The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. ( Li, J; Liu, H; Lu, F; Song, L; Xiao, H; Yang, B; Ye, L; Yin, Y; Zhou, D, 2018)
" In this study, the efficacy of local lidocaine application on anxiety and depression and its curative effect in patients with chronic TTH was investigated."9.17Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. ( Inan, LE; Karadaş, Ö; Odabaşi, Z; Ulaş, Ü, 2013)
"To assess the efficacy of 4% topical lidocaine in spheno-palatine blocks, a randomized controlled trial was carried out on patients with chronic muscle pain syndromes."9.08The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. ( Delaney, G; Heck, C; Janzen, V; McCain, GA; Russell, AL; Scudds, RA; Teasell, RW; Varkey, G; Woodbury, GM, 1995)
"This study evaluated the analgesic efficacy and emotional response to intravenous lidocaine infusion compared with placebo in patients with postherpetic neuralgia (PHN)."5.27The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. ( Li, J; Liu, H; Lu, F; Song, L; Xiao, H; Yang, B; Ye, L; Yin, Y; Zhou, D, 2018)
" In this study, the efficacy of local lidocaine application on anxiety and depression and its curative effect in patients with chronic TTH was investigated."5.17Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. ( Inan, LE; Karadaş, Ö; Odabaşi, Z; Ulaş, Ü, 2013)
"These data show that cerebral protection by lidocaine, which is unrelated to any effect on depression or anxiety, and is at a level that is noticed by the patients."5.09Cerebral protection by lidocaine during cardiac operations. ( Gorman, DF; Mitchell, SJ; Pellett, O, 1999)
"To assess the efficacy of 4% topical lidocaine in spheno-palatine blocks, a randomized controlled trial was carried out on patients with chronic muscle pain syndromes."5.08The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. ( Delaney, G; Heck, C; Janzen, V; McCain, GA; Russell, AL; Scudds, RA; Teasell, RW; Varkey, G; Woodbury, GM, 1995)
"The impact of an outpatient, risk-management system, including a transtelephonic electrocardiographic monitor and lidocaine injector, on the quality of life in post-myocardial infarction patients was examined."5.06Quality of life post-myocardial infarction: effects of a transtelephonic coronary intervention system. ( Capone, RJ; Follick, MJ; Gorkin, L; Smith, TW; Stablein, D; Visco, J, 1988)
" Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications."4.85Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009)
"Provoked vestibulodynia (PVD) is a highly prevalent and debilitating condition yet its management relies mainly on non-empirically validated interventions."2.82Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods. ( Bergeron, S; Dubois, MF; Dumoulin, C; Khalifé, S; Mayrand, MH; Morin, M; Waddell, G, 2016)
"Patients with CRPS type I were treated with standardized pharmacological and physical therapy and were randomized to either TSB or control procedure as an add-on treatment."2.79Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study. ( Cantara, MG; de Andrade, DC; Faria, VG; Liggieri, V; Loduca, A; Müller, BM; Rocha, Rde O; Souza, AC; Teixeira, MJ; Yeng, LT, 2014)
"We tested the hypothesis that ulcerative colitis-like inflammation induced by dextran sodium sulfate (DSS) exacerbates the ongoing spontaneous activity in colon-projecting afferent neurons that induces abdominal discomfort and anxiety, and depressive-like behaviors in rats."1.42Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation. ( Chen, J; Fu, Y; Green, TA; Guptarak, J; Jensen, KL; Sarna, SK; Shi, XZ; Winston, JH, 2015)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19903 (15.00)18.7374
1990's2 (10.00)18.2507
2000's2 (10.00)29.6817
2010's12 (60.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Vivier, D1
Bennis, K1
Lesage, F1
Ducki, S1
Tripathi, SJ1
Chakraborty, S1
Rao, BSS1
Ji, NN1
Kang, J1
Hua, R1
Zhang, YM1
Liu, H1
Lu, F1
Zhou, D1
Yin, Y1
Li, J1
Yang, B1
Song, L1
Ye, L1
Xiao, H1
Karadaş, Ö1
Inan, LE1
Ulaş, Ü1
Odabaşi, Z1
Atalay, NS1
Sahin, F1
Atalay, A1
Akkaya, N1
Rocha, Rde O1
Teixeira, MJ1
Yeng, LT1
Cantara, MG1
Faria, VG1
Liggieri, V1
Loduca, A1
Müller, BM1
Souza, AC1
de Andrade, DC1
Chen, J1
Winston, JH1
Fu, Y1
Guptarak, J1
Jensen, KL1
Shi, XZ1
Green, TA1
Sarna, SK1
Laurent, B1
Vicaut, E1
Leplège, A1
Bloch, K1
Leutenegger, E1
Morin, M1
Dumoulin, C1
Bergeron, S1
Mayrand, MH1
Khalifé, S1
Waddell, G1
Dubois, MF1
Hikiji, W1
Kudo, K1
Nishida, N1
Ishida, T1
Usumoto, Y1
Tsuji, A1
Ikeda, N1
Abernethy, AP1
Farrell, TW1
Ay, S1
Evcik, D1
Tur, BS1
Trevino, K1
McClintock, SM1
Husain, MM1
Berger, A1
Sadosky, A1
Dukes, E1
Edelsberg, J1
Oster, G1
CRONHOLM, B2
OTTOSSON, JO2
Scudds, RA1
Janzen, V1
Delaney, G1
Heck, C1
McCain, GA1
Russell, AL1
Teasell, RW1
Varkey, G1
Woodbury, GM1
Mitchell, SJ1
Pellett, O1
Gorman, DF1
Follick, MJ1
Gorkin, L1
Smith, TW1
Capone, RJ1
Visco, J1
Stablein, D1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Sympathetic Ganglion Block in Patients With Chronic Upper Extremity Neuropathic Pain: a Prospective Randomized and Comparative Clinical Trial[NCT06130514]118 participants (Anticipated)Interventional2023-12-10Not yet recruiting
Efficacy of Treatments for Provoked Vestivulodynia : a Randomised Clinical Trial Comparing Multimodal Physiotherapy Treatments to Topical Lidocaine[NCT01455350]212 participants (Actual)Interventional2011-10-31Completed
Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone[NCT03028012]Phase 410 participants (Actual)Interventional2017-05-02Terminated (stopped due to Poor enrollment.)
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial.[NCT04704297]Phase 4180 participants (Anticipated)Interventional2020-12-28Recruiting
Comparative Study, Between Dry Needling Techniques, in the Evolution of Myofascial Pain Shoulder in Athletes. Elastography as Indicator in the Repair of Myofascial Tissue, Post-dry Needling.[NCT02889991]77 participants (Actual)Interventional2016-05-02Completed
Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011]3 participants (Actual)Observational2020-01-10Terminated (stopped due to PI request - low enrollment)
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With a Responder Rate Greater Than 50% on the Numeric Rating Pain Scale (NRS) Improvement

Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain, one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Post Injections Up to Three Months

InterventionParticipants (Count of Participants)
Ketorolac1
Lidocaine0
Dexamethasone0

Brief Pain Inventory (BPI) - Modified

The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months. (NCT03028012)
Timeframe: Baseline and Three Months

Interventionscore on a scale (Number)
Participant Number #3 at BaselineParticipant Number #3 at 3 MonthsParticipant Number #8 at BaselineParticipant #8 at 3 Months
Ketorolac8353

Numeric Rating Pain Scale (NRS) at Baseline and Three Months.

TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain,one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Injection and Three Month Post Injection(s)

Interventionscore on a scale (Number)
Participant Number 3 at BaselineParticipant Number 3 at 3 MonthsParticipant Number 8 at BaselineParticipant Number 8 at 3 Months
Ketorolac8353

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Reviews

2 reviews available for lidocaine and Depression

ArticleYear
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
    Journal of medicinal chemistry, 2016, 06-09, Volume: 59, Issue:11

    Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc

2016
Pain and palliative care pharmacotherapy literature summaries and analyses.
    Journal of pain & palliative care pharmacotherapy, 2009, Volume: 23, Issue:1

    Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi

2009

Trials

8 trials available for lidocaine and Depression

ArticleYear
The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study.
    The Clinical journal of pain, 2018, Volume: 34, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anxiety; Depression; Double-Blind Method; Emotio

2018
Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache.
    European neurology, 2013, Volume: 70, Issue:1-2

    Topics: Adult; Anesthetics, Local; Anxiety; Depression; Double-Blind Method; Female; Humans; Injections; Lid

2013
Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study.
    Pain, 2014, Volume: 155, Issue:11

    Topics: Adult; Anesthetics, Local; Depression; Disability Evaluation; Double-Blind Method; Female; Follow-Up

2014
Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods.
    Contemporary clinical trials, 2016, Volume: 46

    Topics: Academic Medical Centers; Administration, Topical; Adult; Anesthetics, Local; Anxiety; Catastrophiza

2016
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
    Clinical rheumatology, 2010, Volume: 29, Issue:1

    Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M

2010
The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial.
    Pain, 1995, Volume: 62, Issue:1

    Topics: Administration, Topical; Adult; Anxiety; Autonomic Nerve Block; Chronic Disease; Depression; Double-

1995
Cerebral protection by lidocaine during cardiac operations.
    The Annals of thoracic surgery, 1999, Volume: 67, Issue:4

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Anxiety; Brain Diseases; Depression; Double-Blind Method; Femal

1999
Quality of life post-myocardial infarction: effects of a transtelephonic coronary intervention system.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 1988, Volume: 7, Issue:2

    Topics: Depression; Electrocardiography; Employment; Female; Humans; Interpersonal Relations; Lidocaine; Mal

1988

Other Studies

10 other studies available for lidocaine and Depression

ArticleYear
Remediation of chronic immobilization stress-induced negative affective behaviors and altered metabolism of monoamines in the prefrontal cortex by inactivation of basolateral amygdala.
    Neurochemistry international, 2020, Volume: 141

    Topics: Animals; Anxiety; Basolateral Nuclear Complex; Behavior, Animal; Biogenic Monoamines; Depression; Ib

2020
Involvement of dopamine system in the regulation of the brain corticotropin-releasing hormone in paraventricular nucleus in a rat model of chronic visceral pain.
    Neurological research, 2018, Volume: 40, Issue:8

    Topics: Animals; Animals, Newborn; Central Nervous System Agents; Chronic Pain; Corticotropin-Releasing Horm

2018
Comparison of efficacy of neural therapy and physical therapy in chronic low back pain.
    African journal of traditional, complementary, and alternative medicines : AJTCAM, 2013, Volume: 10, Issue:3

    Topics: Activities of Daily Living; Adult; Anxiety; Depression; Disability Evaluation; Female; Humans; Injec

2013
Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2015, Jan-01, Volume: 308, Issue:1

    Topics: Abdominal Pain; Action Potentials; Anesthetics, Local; Animals; Anxiety; Behavior, Animal; Colitis,

2015
Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: the ZOCAD study.
    Medecine et maladies infectieuses, 2014, Volume: 44, Issue:11-12

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics; Anesthetics, Local; Anticonvu

2014
Acute fatal poisoning with pilsicainide and atenolol.
    International journal of legal medicine, 2008, Volume: 122, Issue:6

    Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Chromatography, High Pressure Liquid; Depression; Fema

2008
The use of topical lidocaine to reduce pain during repetitive transcranial magnetic stimulation for the treatment of depression.
    The journal of ECT, 2011, Volume: 27, Issue:1

    Topics: Adult; Aged; Anesthetics, Local; Depression; Female; Humans; Lidocaine; Male; Middle Aged; Pain; Tra

2011
Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study.
    BMC neurology, 2012, Mar-06, Volume: 12

    Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Stero

2012
Experimental studies of the therapeutic action of electroconvulsive therapy in endogenous depression. The role of the electrical stimulation and of the seizure studied by variation of stimulus intensity and modification by lidocaine of seizure discharge.
    Acta psychiatrica Scandinavica. Supplementum, 1960, Volume: 35, Issue:145

    Topics: Convulsive Therapy; Depression; Depressive Disorder; Electric Stimulation; Electroconvulsive Therapy

1960
ULTRABRIEF STIMULUS TECHNIQUE IN ELECTROCONVULSIVE THERAPY. I. INFLUENCE ON RETROGRADE AMNESIA OF TREATMENTS WITH THE ELTHER ES ELECTROSCHOCK APPARATUS, SIEMENS KONVULSATOR III AND OF LIDOCAINE-MODIFIED TREATMENT.
    The Journal of nervous and mental disease, 1963, Volume: 137

    Topics: Amnesia; Amnesia, Retrograde; Depression; Depressive Disorder; Electroconvulsive Therapy; Humans; Li

1963